講演情報
[O21-4]Three-year survival, safety and extended long-term survivor (eLTS) analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer
*Okusaka T1、Oh D-Y2、He A R3、Qin S4、Chen L-T5、Vogel A6、Kim J W7、Suksombooncharoen T8、Lee M A9、Kitano M10、Burris H A.11、Tanasanvimon S12、Cundom J13、Valle J W.14 (1.NationalCancerCenterHospital、2.SeoulNationalUniversityHospital、3.LombardiComprehensiveCancerCenter、4.JinlingHospital、5.KaohsiungMedicalUniversityHospital、6.TorontoGeneralHospital、7.SeoulNationalUniversityBundangHospital、8.ChiangMaiUniversity、9.SeoulSt.Mary’sHospital、10.WakayamaMedicalUniversity、11.SarahCannonResearchInstitute、12.KingChulalongkornMemorialHospital、13.InstitutodeInvestigacionesMetabólicas、14.CholangiocarcinomaFoundation)